- Quest Diagnostics 2024 adjusted EPS forecast is projected to be between $8.60 to $8.90, missing the estimate of $8.98.
- The fourth quarter results show an adjusted EPS of $2.15, surpassing the estimate of $2.11.
- The net revenue for the fourth quarter was $2.29 billion, surpassing the estimate of $2.25 billion.
- The diagnostics revenue for the same quarter was $2.22 billion, surpassing the estimate of $2.17 billion.
- The adjusted operating profit for the fourth quarter was $338 million, falling short of the estimate of $365.5 million.
- The adjusted operating margin was 14.8%, falling short of the estimate of 16.2%.
- The capital expenditure for the fourth quarter was $72 million, surpassing the estimate of $67.9 million.
- The full year 2024 reported diluted EPS is expected to be between $7.69 and $7.99.
- The adjusted diluted EPS for the full year 2024 is expected to be between $8.60 and $8.90.
- Mr. Davis stated that the guidance for 2024 reflects a return to overall revenue growth while balancing the earnings tailwinds and headwinds for the year.
- The current standing of Quest Diagnostics is 5 buys, 14 holds, and 0 sells.
Quest Diagnostics on Smartkarma
In recent news, Quest Diagnostics has been generating buzz on Smartkarma, an independent investment research network. According to a report by Baptista Research, Quest Diagnostics has been making strides in the healthcare industry, with their recent acquisition of Haystack and enhancements to their cancer diagnostics portfolio. The report, titled “Quest Diagnostics: Can The Haystack Acquisition & The Enhancements To The Cancer Diagnostics Portfolio Give Them A Boost? – Key Drivers,” highlights the company’s strong performance and focus on driving growth through specialized advanced diagnostics, acquisitions, and operational improvements. Baptista Research has given Quest Diagnostics Incorporated a ‘Hold’ rating with a revised target price.
A look at Quest Diagnostics Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.8 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Quest Diagnostics has a promising long-term outlook, according to the Smartkarma Smart Scores. The company received a score of 3 for value, indicating that it is reasonably priced for its current performance. Additionally, Quest Diagnostics received a score of 3 for growth, suggesting that the company has potential for future growth. This is supported by its strong momentum score of 4, indicating that the company is currently performing well.
While Quest Diagnostics received a lower score of 2 for both dividend and resilience, this does not necessarily indicate a negative outlook. The company still provides diagnostic testing, information, and services through its national network of laboratories and patient service centers. It also offers a variety of testing options, including esoteric, routine medical, and drugs of abuse testing. Overall, Quest Diagnostics is a strong company with a promising outlook for the future.
Summary: Quest Diagnostics is a company that provides diagnostic testing, information, and services through a national network of laboratories and patient service centers. It offers a variety of testing options, including esoteric, routine medical, and drugs of abuse testing. According to the Smartkarma Smart Scores, the company has a promising long-term outlook with strong potential for growth and current positive momentum.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
